Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • imsharmanitin
    Postdoc Cancer Bioinformatics
    • Dec 2014
    • 17

    #1

    Salmon's strategy for aggregating transcripts into gene level

    I am new in the field on RNA-Seq analysis and trying to understand the methodology behind Salmon's aggregation of transcripts into gene level.

    From the forum https://github.com/COMBINE-lab/salmon/issues/98 The answer is "Salmon's aggregation strategy is to collect the transcript-level abundances and then aggregate them to the gene level (this means summing the counts / TPMs, and doing an abundance weighted combination of the lengths / effective lengths)." However, I was not able to understand is properly.

    can someone explain it in detail for this example where the quantification at transcript level and its aggregated output at gene level are shown?

    Name Length EffectiveLength TPM NumReads

    ENSG00000172530 78.6693 60.7441 9.11087 516.593

    ENST00000569400 802 553 0.0341855 1.27033
    ENST00000423252 644 395 0.0573103 1.52117
    ENST00000488074 759 510 0 0
    ENST00000439677 736 487 1.10087 36.0257
    ENST00000454563 558 309 0 0
    ENST00000479780 1551 1302 0.382663 33.4793
    ENST00000393208 2283 2034 0.374088 51.1297
    ENST00000459966 627 378 0 0
    ENST00000412691 586 337 1.58787 35.9578
    ENST00000526460 547 298 0 0


    Moreover, I will like to know how it is different from simplesum_avetxl used in Tximport mentioned in the paper "Differential analyses for RNA-seq: transcript-level estimates improve gene-level inferences"?

    In addition, will it be wrong to use "quant.genes.sf" instead of "quants.sf" as input for Tximport? if yes, then why?
    Last edited by imsharmanitin; 05-26-2017, 05:55 AM. Reason: adding more information

Latest Articles

Collapse

  • SEQadmin2
    Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
    by SEQadmin2



    Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

    Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
    ...
    10-14-2026, 09:55 AM
  • SEQadmin2
    New Genomics Technologies Take Aim at Long-Standing Limits
    by SEQadmin2


    Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

    We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
    ...
    09-28-2026, 10:25 AM

ad_right_rmr

Collapse

News

Collapse

Topics Statistics Last Post
Started by SEQadmin2, 10-22-2026, 11:13 AM
0 responses
27 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-22-2026, 10:48 AM
0 responses
20 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-15-2026, 10:52 AM
0 responses
36 views
0 reactions
Last Post SEQadmin2  
Started by SEQadmin2, 10-14-2026, 05:39 AM
0 responses
43 views
0 reactions
Last Post SEQadmin2  
Working...